Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to higher biopsy‐proven acute rejection compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 1.7 [1.32, 2.19]
15 studies · 3309 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: primary outcomes

Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in biopsy‐proven acute rejection compared with antimetabolites: primary outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.95 [0.81, 1.12]
24 studies · 10101 participants
Moderate